Contact:

Dr. Robert Zahradnik                                               Joan Kureczka
President and Chief Executive Officer                 Kureczka/Martin Associates
Oragenics, Inc.                                                   (415) 821-2413
(386) 418-4018                                             Jkureczka@comcast.net

FOR IMMEDIATE RELEASE

               Oragenics Names New Interim Chief Executive Officer

ALACHUA, FL (July 6, 2005) - Oragenics, Inc. (AMEX: ONI) today announced that
Dr. Robert T. Zahradnik has been named acting president and chief executive
officer. Dr. Zahradnik replaces Mento A. Soponis who is retiring and has
resigned as an officer of the company. Mr. Soponis will continue to serve on the
company's Board of Directors. The Board is undertaking a search for a new CEO.

Dr. Zahradnik, a co-founder of Oragenics, has been a member of the company's
Board of Directors since November 1996. Prior to rejoining Oragenics, Dr.
Zahradnik spent his career with Johnson & Johnson in various R&D management
positions, with Advanced Clinical Technologies as chairman and CEO, and as
partner and general manager at Pro-Dentec Therapeutics. "The addition of Dr.
Zahradnik to the senior management team, with his extensive experience in
product development, underscores the Company's commitment to broaden its
experience base and prepare for its next stage of growth," commented David J.
Gury, chairman of the Board of Directors.

About Oragenics

Oragenics, Inc. is an emerging biotechnology company focused on the development
and licensure of innovative products and technologies for improving human
health. The company's lead product is a novel oral rinse for the prevention of
tooth decay. The company is also developing a novel antibiotic with
broad-spectrum activity against gram-positive bacteria and a probiotic product
aimed at maintaining oral health. The company is headquartered in Alachua,
Florida. For more information about Oragenics, please consult the company's
website at www.oragenics.com.


Oragenics Names New Interim CEO
Page 2

Safe Harbor Statement Under the Private Securities Litigation Reform Act of
1995: This release includes forward-looking statements that reflect Oragenics'
current views with respect to future events and financial performance. These
forward-looking statements are based on management's beliefs and assumptions and
information currently available. The words "believe", "expect", "anticipate",
"intend", "estimate", "project" and similar expressions that do not relate
solely to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they are
subject to a variety of risks, uncertainties, and other factors that could cause
actual results to differ materially from those expressed in any such
forward-looking statements. These factors include, but are not limited to (1)
the ability to successfully complete development and commercialization of
Oragenics' Replacement Therapy for prevention of tooth decay, novel antibiotic,
and probiotic product for oral health; (2) the ability to obtain substantial
additional funding; (3) the ability to develop and commercialize products before
competitors;)4) the ability to develop commercial products with the in-licensed
technology; and (5)) other factors detailed from time to time in filings with
the Securities and Exchange Commission. We expressly disclaim any responsibility
to update forward-looking statements. .


                                      # # #